1. IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY. (June 2017) Authors: Rule, S.; Jurczak, W.; Jerkeman, M.; Santucci Silva, R.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens‐Harig, M.; Hess, G.; Bence‐Bruckler, I.; Cho, S.; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.D.; Vermeulen, J.; Dreyling, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P938: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET). (23rd June 2022) Authors: Nørgaard, J. N.; Abildgaard, N.; Lysén, A.; Tsykunova, G.; Vangsted, A. J.; Joao, C.; Remen, N.; Osnes, L.; Connelly, J. P.; Revheim, M.-E. R.; Schjesvold, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 828 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗